Clarity Pharmaceuticals

Congrats to Dr Alan Taylor and the entire Clarity Pharmaceuticals team on your IPO today (ASX:CU6). A strong debut above the IPO price. Sydney Angels has been pleased to have been able to support you over the last 10 years. What a spectacular outcome for all. Well done. https://lnkd.in/gKU946aH

Congratulations to Sydney Angels Portfolio Company eBev

Congratulations to eBev (a Sydney Angels portfolio company) for the launch of eBev Trade, clearly much needed in this environment!!

NEW eBev Trade provides cost savings to licensed venues and their beverage suppliers plus a much-needed cash boost to the industry. eBev - Australia’s largest online beverage ordering platform - now builds on its expertise in order management with the addition of eBev Trade credit and payment facilities.

Opportunities for Early-Stage Start-up investment in times of economic uncertainty

Sydney Angels is still investing in startups with high potential. “There’s a lot of negative speculation around whether early-stage tech companies will get the funding needed to rapidly grow, given the huge uncertainty facing investors. "Tech startups are an extremely important sector of the economy and will drive a significant portion of Australia’s economic recovery. We believe it’s more crucial than ever to support early-stage companies with capital for growth..." Adrian Bunter from Sydney Angels speaks to Startup Daily. about the opportunities for early-stage start up investment in times of economic uncertainty.

Atomo Diagnostics lists on the ASX

Sydney Angels portfolio company Atomo Diagnostics listed on the ASX (ASX:AT1) on 16 April. A few far sighted Sydney Angels members invested in Atomo starting back in 2010 - and their investment has been worth it - with the closing price on the first day representing more than 10x return on investment (based on the closing price of $0.39). Congratulations to Atomo and its investors. Atomo is a global leader in pathology on a stick diagnostic kits and has achieved remarkable success, especially with its HIV test in developing countries without a network of pathology labs. One of its key investors is the Bill & Melinda Gates Foundation.